Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

May 2018 – Cancer Biomarkers and Molecular Testing

Gilotrif Approved as First Treatment for Metastatic Lung Cancer and EGFR Mutations


Erleada First Drug Approved for Patients with Nonmetastatic Prostate Cancer
On February 14, 2018, the FDA approved Erleada (apalutamide; from Janssen) for the treatment of patients with nonmetastatic, castration-resistant prostate cancer. Read More ›

Verzenio Approved as Initial Treatment for Metastatic Breast Cancer
The CDK4/CDK6 inhibitor Verzenio received a new indication, for use alone or in combination with an aromatase inhibitor, as initial therapy in women with HR-positive, HER2-negative advanced or metastatic breast cancer. Read More ›

Imfinzi Approved to Reduce Cancer Progression in Stage III Lung Cancer

Tagrisso Now Approved as First Treatment for Metastatic NSCLC and EGFR Mutations

Adcetris Approved as Initial Treatment for Advanced Classical Hodgkin Lymphoma

Zytiga Approved for New Type of Metastatic Prostate Cancer

Blincyto First Drug Approved for ALL and the MRD Biomarker
This is the first time the FDA has used minimal residual disease (MRD) as a biomarker to approve a specific treatment for patients with acute lymphoblastic leukemia (ALL). Read More ›

From Silent Voices to “Hear My Voice”: People Living with Metastatic Breast Cancer Are Speaking Out
A national advocacy program trains patients with metastatic breast cancer to educate the public about the special needs of patients with advanced breast cancer. Read More ›

Page 1 of 3